#BEGIN_DRUGCARD DB08798

# AHFS_Codes:
Not Available

# ATC_Codes:
J01EC03

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Justamil
Sulfavigor
Sulfmidil
Tardamid
Vetranal

# CAS_Registry_Number:
729-99-7

# ChEBI_ID:
55548

# Chemical_Formula:
C11H13N3O3S

# Chemical_IUPAC_Name:
4-amino-N-(dimethyl-1,3-oxazol-2-yl)benzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2010-10-14 13:40:39 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Sulfamoxole is a sulfonamide antibacterial.

# Dosage_Forms:
Not Available

# Drug_Category:
Antibacterial Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
13888264	DUGGER JA: Sulfamoxole (Nuprin), a new sulfonamide, in pediatric practice. J New Drugs. 1961 Sep-Oct;1:223-9.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1680 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sulfamoxole

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H13N3O3S/c1-7-8(2)17-11(13-7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6H,12H2,1-2H3,(H,13,14)

# InChI_Key:
InChIKey=CYFLXLSBHQBMFT-UHFFFAOYSA-N

# Indication:
For the treatment of bacterial infection.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02516

# LIMS_Drug_ID:
8804

# Mechanism_Of_Action:
Sulfamoxole is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

# Melting_Point:
193 °C

# Molecular_Weight_Avg:
267.304

# Molecular_Weight_Mono:
267.067761987

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA165958417

# Pharmacology:
Sulfamoxole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

# Predicted_LogP_Hydrophobicity:
1.04

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
2.67e-01 g/l

# Primary_Accession_No:
DB08798

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=C(C)N=C(NS(=O)(=O)C2=CC=C(N)C=C2)O1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Sulfamoxol
Sulfamoxolum
Sulfono
Sulphamoxole

# Synthesis_Reference:
Not Available

# Toxicity:
Oral Rat LD50: > 12500 mg/kg; Intravenous Mouse LD50: 1 g/kg

# Update_Date:
2013-02-08 16:27:17 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sulfamoxole

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
9127492	Prabhu V, Lui H, King J: Arabidopsis dihydropteroate synthase: general properties and inhibition by reaction product and sulfonamides. Phytochemistry. 1997 May;45(1):23-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Z30658

# Drug_Target_1_GenBank_ID_Protein:
505177

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
>1115 bp
TGATACCCGAATATAAGCATAATGTTTTAAATAATACCATCAGATGTTTATATAACAAAT
ATGTGAGTAGGATGAAAGAACAATATAATATAAATATTAAAGAAAATAATAAAAGGATAT
ATGTATTAAAAGATAGAATTTCTTATTTAAAAGAAAAAACAAATATTGTTGGAATATTAA
ATGTTAATTATGATTCTTTTTCAGATGGAGGTATTTTTGTTGAACCTAAACGTGCTGTTC
AAAGAATGTTTGAAATGATAAATGAAGGTGCTAGTGTTATAGATATAGGTGGAGAATCCG
CTGGTCCTTTTGTTATACCTAATCCAAAAATTAGTGAAAGAGATTTAGTAGTACCTGTAT
TACAATTATTTCAAAAAGAATGGAATGATATAAAAAATAAAATTGTTAAATGTGATGCGA
AACCAATTATAAGTATTGATACAATTAACTATAATGTTTTTAAAGAATGTGTTGATAATG
ATTTAGTTGATATATTAAATGATATTAGTGCTTGTACAAATAATCCAGAAATTATAAAAT
TATTAAAAAAAAAAAACAAATTCTATAGTGTAGTTCTAATGCATAAAAGAGGAAATCCAC
ATACAATGGATAAACTAACAAATTATGATAATCTAGTTTATGATATAAAAAATTATTTAG
AACAAAGATTAAATTTTCTTGTATTAAATGGAATACCTCGTTATAGGATACTATTTGATA
TTGGATTAGGATTTGCGAAGAAACATGATCAATCTATTAAACTCTTACAAAATATACATG
TATATGATGAGTATCCACTTTTTATTGGATATTCAAGAAAAAGATTTATTGCCCATTGCA
TGAATGATCAAAATGTTGTAATAAATACACAACAAAAATTACATGATGAACAACAAAATG
AAAATAAAAATATTGTGGACAAATCACACAATTGGATGTTTCAGATGAATTACATGAGGA
AAGACAAGGATCAACTTTTATATCAAAAAAATATATGTGGTGGATTAGCAATTGCTTCCT
ACAGCTATTATAAAAAGGTAGATCTAATAAGAGTTCATGACGTTTTAGAAACAAAATCGG
TTTTGGATGTTTTAACAAAAATAGACCAAGTGTAA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
7925353	Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994 Sep 1;224(2):397-405.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4116

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
43372

# Drug_Target_1_Name:
Dihydropteroate synthetase

# Drug_Target_1_Number_of_Residues:
370

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropteroate synthetase
IPEYKHNVLNNTIRCLYNKYVSRMKEQYNINIKENNKRIYVLKDRISYLKEKTNIVGILN
VNYDSFSDGGIFVEPKRAVQRMFEMINEGASVIDIGGESAGPFVIPNPKISERDLVVPVL
QLFQKEWNDIKNKIVKCDAKPIISIDTINYNVFKECVDNDLVDILNDISACTNNPEIIKL
LKKKNKFYSVVLMHKRGNPHTMDKLTNYDNLVYDIKNYLEQRLNFLVLNGIPRYRILFDI
GLGFAKKHDQSIKLLQNIHVYDEYPLFIGYSRKRFIAHCMNDQNVVINTQQKLHDEQQNE
NKNIVDKSHNWMFQMNYMRKDKDQLLYQKNICGGLAIASYSYYKKVDLIRVHDVLETKSV
LDVLTKIDQV

# Drug_Target_1_Reaction:
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate + 4-aminobenzoate = diphosphate + 7,8-dihydropteroate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q27738

# Drug_Target_1_SwissProt_Name:
Q27738_PLAFA

# Drug_Target_1_Synonyms:
EC 2.5.1.15

# Drug_Target_1_Theoretical_pI:
9.19

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB08798
